1155287-27-6 Usage
Uses
Used in Pharmaceutical Research:
2-Amino-4-bromo-benzothiazole-6-carboxylic acid methyl ester is used as a key intermediate in pharmaceutical research for the synthesis of various drug candidates. Its unique structure allows for the creation of novel compounds with potential therapeutic applications.
Used in Organic Synthesis:
In the field of organic synthesis, 2-amino-4-bromo-benzothiazole-6-carboxylic acid methyl ester serves as a versatile building block for the development of complex organic molecules. Its reactivity and functional groups make it suitable for a wide range of chemical reactions, contributing to the advancement of organic chemistry.
It is crucial to handle 2-amino-4-bromo-benzothiazole-6-carboxylic acid methyl ester with care and follow proper safety protocols due to its potential hazards, ensuring the safety of researchers and the environment.
Check Digit Verification of cas no
The CAS Registry Mumber 1155287-27-6 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,1,5,5,2,8 and 7 respectively; the second part has 2 digits, 2 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 1155287-27:
(9*1)+(8*1)+(7*5)+(6*5)+(5*2)+(4*8)+(3*7)+(2*2)+(1*7)=156
156 % 10 = 6
So 1155287-27-6 is a valid CAS Registry Number.
1155287-27-6Relevant articles and documents
COMPOSITIONS AND METHODS FOR MODULATING FXR
-
Page/Page column 113; 114, (2012/07/13)
The present invention relates to compounds of Formula (I), a stereoisomer, enantiomer, a pharmaceutically acceptable salt or an amino acid conjugate thereof; wherein variables are as defined herein; and their pharmaceutical compositions, which are useful as modulators of the activity of Farnesiod X receptors (FXR).
SUBSTITUTED BENZOAZOLE PDE4 INHIBITORS FOR TREATING PULMONARY AND CARDIOVASCULAR DISORDERS
-
Page/Page column 22; 23, (2009/05/28)
The invention relates to substituted benzothiazoles, benzoxazoles—and their counterparts having pyridine and pyrimidine rings replacing the benzene ring—that are PDE4 inhibitors useful for treating stroke, myocardial infarct, and cardiovascular inflammatory conditions, to pharmaceutical compositions comprising these compounds, and to methods for the treatment of stroke, myocardial infarct, and cardiovascular inflammatory conditions in a mammal. The compounds have general formula I: in which A and B are carbocycles or heterocycles. A particular embodiment is
